The Board of Directors of Solara Active Pharma Sciences Limited, at their meeting held on May 15, 2026, approved the re-appointment of both the Internal Auditors and Cost Auditors of the company for the financial year 2026-27. The decision was disclosed to the stock exchanges in accordance with Regulation 30 read with Para A, Part-A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI Master Circular dated January 30, 2026.

Auditor Re-Appointments at a Glance

The following table summarises the key details of both re-appointments as disclosed by the company:

Profile of the Internal Auditor

M/s. Grant Thornton Bharat LLP is described as one of the leading professional service firms offering business advisory services for foreign and Indian companies. The firm works with businesses and government entities across industries and sectors, providing a broad range of services including assurance, consulting, tax, risk, regulatory, finance, and digital and technology transformation services.

Profile of the Cost Auditor

Mr. K. Suryanarayanan is a Fellow member of the Institute of Cost Accountants of India with more than two decades of experience in Finance, Accounts, MIS, Costing, and Taxation. He has served as a faculty member of the Institute of Cost Accountants of India and other management institutes, handling Cost Accounting Standards and Cost Audit for final students of CA and CMA programmes. He is also a visiting faculty to government and non-government entities and has conducted special audits and desk reviews under the provisions of Indirect Tax for reputed multinationals. Additionally, he has handled various assignments connected to Insurance and Transfer Pricing.

Regulatory Compliance

The re-appointments were made in compliance with the applicable provisions of the SEBI Listing Regulations. The company confirmed that there are no relationships between the re-appointed auditors and the directors of the company. The disclosure was signed by Pooja Jaya Kumar, Company Secretary and Compliance Officer (Membership No.: A57415), on behalf of Solara Active Pharma Sciences Limited.

Solara Active Pharma Sciences has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration for its Puducherry manufacturing facility. The regulatory development marks a significant milestone for the pharmaceutical company's operations at this location.

FDA Inspection Timeline and Outcome

The US FDA conducted an unannounced inspection of the Puducherry facility from February 2 to February 6, 2026. The inspection has been concluded with a Voluntary Action Indicated (VAI) status, with the agency issuing the EIR on April 24, 2026, and marking the inspection as "Closed".

Management Commentary

Commenting on the inspection outcome, Sandeep Rao, MD & CEO, stated that the company successfully completed the FDA inspection at the Puducherry facility. At the end of the inspection, four Form FDA 483 inspectional observations were issued by the investigator, which were procedural in nature. The company submitted its formal response to FDA within the stipulated timeline.

"The inspection outcome demonstrates our commitment to regulatory excellence at our global manufacturing sites and relentless focus on world-class quality and compliance, which remains a key pillar of our growth strategy," Rao added.

Facility Specifications

The Puducherry site serves as an Ibuprofen manufacturing facility equipped with world-class infrastructure to cater to Ibuprofen and its derivatives requirements for domestic and international markets. The facility has been inspected by various regulatory authorities including US FDA, EDQM, MHRA, and HPRA.

Regulatory Significance

The VAI status represents a favorable outcome for pharmaceutical manufacturing facilities undergoing FDA inspection. This classification demonstrates that the Puducherry facility maintains appropriate manufacturing practices and quality standards as required by US regulatory authorities. The successful closure of the unannounced inspection exhibits the company's dedication to achieving quality excellence consistently across all manufacturing sites.